APA (7th ed.) Citation

NA, K., J, M., KL, R., CM, G., LA, B., YQ, Z., . . . K, K. (2025). Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 20(3), 383. https://doi.org/10.1016/j.jtho.2024.10.021

Chicago Style (17th ed.) Citation

NA, Karim, et al. "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 20, no. 3 (2025): 383. https://doi.org/10.1016/j.jtho.2024.10.021.

MLA (9th ed.) Citation

NA, Karim, et al. "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 20, no. 3, 2025, p. 383, https://doi.org/10.1016/j.jtho.2024.10.021.